Drugs / PZ-128
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01806077 | Apr 2013 → Nov 2014 | coronary artery disorder | Tufts Medical Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02561000 | May 2016 → Sep 2019 | acute coronary syndrome, arterial occlusion, arteriosclerosis disorder, coronary artery disorder | Tufts Medical Center | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PZ-128 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02561000 ↗ |
| Known as | Palmitate-kksralf-nh2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297323 ↗ |
| Action | Inhibit | “Proteinase-activated receptor 1 inhibitor” CHEMBL4297323 ↗1“pepducin inhibitor of PAR1” NCT01806077 ↗ |
| Modality | Peptide | “pepducin inhibitor of PAR1” NCT01806077 ↗ |
| Route | Intravenous | “1 to 2 hour continuous intravenous infusion” NCT01806077 ↗ |
| Target | F2R | “Proteinase-activated receptor 1 inhibitor” CHEMBL4297323 ↗ |